ReviewCureus2025
Retreatment and Reactivation Rates Following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reported Retinal Detachment in Anti-VEGF-Treated Retinopathy of Prematurity: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinopathy of prematurity (ROP) is a vasoproliferative retinal disorder that affects preterm newborns. Although laser therapy has been the standard of care for ROP for decades, the use of anti-VEGF agents for ROP has recently become widespread. This systematic review and meta-analysis measures and compares the retreatment and reactivation rates following laser therapy versus anti-vascular endothelial growth factor (VEGF) agents and laser for ROP. We searched Medline, Scopus, Clinical Trial, and Cochrane Library databases for all randomized controlled trials (RCTs) that have used bevacizumab, ranibizumab, aflibercept, or laser therapy for ROP. We assessed studies for risk of bias by the Critical Appraisal Skills Programme (CASP) criteria. Review Manager (RevMan) (2014) Version 5.3 was utilized to carry out the meta-analysis for our study. Five studies were included in this review. The meta-analysis has revealed that laser treatment is associated with a significantly lower risk of retreatment than anti-VEGF medications (RR = 2.11, 95% CI 1.46-3.05, p < 0.0001, I² = 92%). In the subgroup analysis conducted based on the type of anti-VEGF medication used, studies using Aflibercept and Ranibizumab reported higher retreatment rates than studies with Bevacizumab. Similarly, there was a significant difference in terms of the reactivation rates, with patients who underwent laser therapy exhibiting lower reactivation rates than the anti-VEGF groups (RR = 2.00, 95% CI: 1.47 to 2.72, p < 0.0001, I² = 93%). The subgroup analysis comparing types of anti-VEGF agents has also displayed both ranibizumab and aflibercept to have higher reactivation rates than bevacizumab. This meta-analysis demonstrates that laser therapy generally presents a notably reduced risk of retreatment and reactivation compared to ranibizumab and aflibercept, in line with prior research. Conversely, the study reveals that bevacizumab outperforms laser therapy, exhibiting lower rates of retreatment and reactivation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.